These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28353093)

  • 21. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
    Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
    Leite KR; Reis ST; Junior JP; Zerati M; Gomes Dde O; Camara-Lopes LH; Srougi M
    Diagn Pathol; 2015 Oct; 10():189. PubMed ID: 26470780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
    Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
    Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
    Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Shariftabrizi A; Rasti A; Asgari M
    Cancer Biomark; 2018; 21(4):821-837. PubMed ID: 29286924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
    Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
    Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of PD-1 and its ligands in renal cell carcinoma.
    Erlmeier F; Weichert W; Schrader AJ; Autenrieth M; Hartmann A; Steffens S; Ivanyi P
    Med Oncol; 2017 Jun; 34(6):99. PubMed ID: 28432616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of claudin-6 in chromophobe renal cell carcinoma.
    Erlmeier F; Zschäbitz S; Mikuteit M; Autenrieth M; Weichert W; Hartmann A; Steffens S
    Histol Histopathol; 2023 Apr; 38(4):403-407. PubMed ID: 36128931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.
    Mikuteit M; Steffens S; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Erlmeier F
    Oncology; 2022; 100(6):331-336. PubMed ID: 35168242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
    Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
    Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma.
    Arik D; Can C; Dündar E; Kabukçuoğlu S; Paşaoğlu Ö
    Pathol Oncol Res; 2017 Apr; 23(2):409-416. PubMed ID: 27738793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
    Mikuteit M; Zschäbitz S; Erlmeier M; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    Oncology; 2022; 100(10):536-541. PubMed ID: 35760058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HNF1β and S100A1 are useful biomarkers for distinguishing renal oncocytoma and chromophobe renal cell carcinoma in FNA and core needle biopsies.
    Conner JR; Hirsch MS; Jo VY
    Cancer Cytopathol; 2015 May; 123(5):298-305. PubMed ID: 25739652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
    Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y
    Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.